Alaunos raises $1.1M in registered direct offering for obesity drug work
What's the deal? Alaunos Therapeutics (Nasdaq: TCRT) has priced a registered direct offering for roughly $1.1 million in gross proceeds. The Fort Lauderdale biotech is selling 380,469 shares and pre-funded warrants for up to 386,654 shares at $1.46 apiece. It expects the deal to close on or about September 21, 2026.
Who's involved? Institutional investors are buying into the offering, which was priced at-the-market under Nasdaq rules. Dawson James SecuritiesDealroom has a profile for this one. Try Dealroom → is acting as sole placement agent.
What's the endgame? Alaunos plans to use the net proceeds primarily for general working capital and corporate purposes. Its lead program, ALN1003, is an oral small-molecule candidate for obesity and metabolic disorders. The company frames it as a "non-hormonal, non-incretin" approach — a contrast to the injectable incretin drugs that dominate the current obesity market.
Why now? The offering draws on a shelf registration statement filed with the US Securities and Exchange Commission in November 2025 that became effective on December 1, 2025.
The signal: The raise is modest, but it keeps a small-cap biotech funded as it advances an early obesity candidate. With demand for weight-loss therapies still climbing, even micro-cap players are angling for a differentiated lane against the incretin heavyweights.
Read more: pr.lakeoconeebreeze.net
Image credit: Click2pharmacy.co.uk Images
